摘要
介绍:勃起功能障碍(ED)已经达到了流行病的比例,且因为人口老龄化和伴随着高龄而出现的慢性病而不会减弱。血管病变是一个主要原因,但损害阴茎神经支配在血多ED患者中也出现。磷酸二酯酶抑制剂治疗并不能帮助所有的ED男性患者,这使得寻找新的治疗药物和治疗靶点变得至关重要。目的:对文献进行综述从而确定潜在的新的治疗靶点以填补男性ED治疗选择,聚焦于血管原性ED的治疗,但是包括新颖的由于阴茎神经损伤的ED的治疗靶点,一个常见的男性盆腔手术结果。方法:检索了最近的关于体内,体外和临床前和人类观察性研究的文献出版物,可能时,将识别潜在的ED治疗新靶标,而不是广泛的进行综述。结果:文献检索确定微粒,髓过氧化物酶和血红素加氧酶-1作为新兴的治疗血管性ED的分子靶点。新颖的再生治疗靶点,包括音速因子,甘丙肽,和细胞治疗,也对由于阴茎损伤引起的ED的潜在未来治疗进行了综述。结论:新颖的分子靶点和细胞治疗为ED治疗的进步提供了巨大的希望。处于对这些靶点的功效,毒性,偏离目标效果,安全,和使用方便性的担心,还有大量的工作要做从而确认这些作为有效的ED治疗的可行的追求目标。本文中为感兴趣的读者引用了所讨论的补充靶点的相关文献。
关键词: 勃起功能障碍,血红素氧合酶-1,微粒,绿过氧物酶,血小板,再生治疗,血管炎症
Current Drug Targets
Title:Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon
Volume: 16 Issue: 5
Author(s): Inger Stallmann-Jorgensen and R. Clinton Webb
Affiliation:
关键词: 勃起功能障碍,血红素氧合酶-1,微粒,绿过氧物酶,血小板,再生治疗,血管炎症
摘要: Introduction: Erectile dysfunction (ED) has reached epidemic proportions not expected to abate because of population aging and chronic diseases that accompany advanced age. Vasculopathy is a main cause, but damage to penile innervation also underlies many cases of ED. Phosphodiesterase inhibitor therapies do not help all men with ED, making the search for novel therapeutic drug and treatment targets of utmost importance. Aims: To review the literature to identify potential new treatment targets to fill a gap in therapeutic options for men with ED, with a focus on treatments for vasculogenic ED, but including novel treatment targets for ED due to penile nerve damage, a frequent consequence of pelvic surgery in men. Methods: The recent literature was searched for publications on in vitro, in vivo, pre-clinical and observational human studies, when available, that would identify potential new targets for ED therapies not previously, or not extensively reviewed. Results: Literature searches identified microparticles, myeloperoxidase, and heme oxygenase-1 as emerging molecular targets to treat vasculogenic ED. Novel regenerative therapy targets, including sonic hedgehog, galanin, and cell-based treatments were also reviewed as potential future treatments for ED due to damage to penile innervation. Conclusion: Novel molecular targets and cell-based therapies offer great hope for advances in ED treatment. Concerns regarding efficacy, toxicity, off target effects, safety, and convenience apply to these targets; much work remains to confirm these as viable targets to pursue for effective ED treatments. To complement targets discussed in this review relevant review papers were cited for the interested reader. To complement targets discussed in this review relevant review papers were cited for the interested reader
Export Options
About this article
Cite this article as:
Inger Stallmann-Jorgensen and R. Clinton Webb , Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon, Current Drug Targets 2015; 16 (5) . https://dx.doi.org/10.2174/1389450116666150427160710
DOI https://dx.doi.org/10.2174/1389450116666150427160710 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Long-Term Effects of Perinatal Glucocorticoid Treatment on the Heart
Current Pediatric Reviews In Vivo Imaging of Apoptosis in Cancer: Potentials and Drawbacks of Molecular Probes
Current Molecular Imaging (Discontinued) Proteomic Analysis of Endothelin-1 Targets in the Regulation of Cardiomyocyte Proliferation
Current Topics in Medicinal Chemistry The Hepatic Lipidome: A Gateway to Understanding the Pathogenes is of Alcohol-Induced Fatty Liver
Current Molecular Pharmacology Phosphorylated and O-GlcNAc Modified IRS-1 (Ser1101) and -2 (Ser1149) Contribute to Human Diabetes Type II
Protein & Peptide Letters Invasive and Noninvasive Assessment of Exercise-induced Ischemic Diastolic Response Using Pressure Transducers
Current Cardiology Reviews Current Concepts on Prenatal Diagnosis and Management of Fetal Tachyarrythmias
Current Cardiology Reviews Genomic Databases and the Search of Protein Targets for Protozoan Parasites
Current Drug Targets Pregnancy Complicated by the Most Frequent Forms of Maturity Onset Diabetes of the Young: A Narrative Review on Its Pharmacological Implications
Current Reviews in Clinical and Experimental Pharmacology Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy
Current Pharmaceutical Design Meet Our Editor:
Current Cardiology Reviews Rewiring the Heart: Stem Cell Therapy to Restore Normal Cardiac Excitability and Conduction
Current Stem Cell Research & Therapy The Anti-Oxidant Properties of Isothiocyanates: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Molecular Aspects of Modulation of L-type Calcium Channels by Protein Kinase C
Current Molecular Pharmacology L-Type Calcium Channels
Current Pharmaceutical Design Ubiquitin and ubiquitin-like proteins in cardiac disease and protection
Current Drug Targets Bone Marrow Stem Cell Therapy for Myocardial Angiogenesis
Current Vascular Pharmacology Levosimendan Reduces Prostaglandin F2a-dependent Vasoconstriction in Physiological Vessels and After Experimentally Induced Subarachnoid Hemorrhage
Current Neurovascular Research Treating Nonthyroidal Illness Syndrome in the Critically Ill Patient: Still a Matter of Controversy
Current Drug Targets Apelin in the Control of Body Fluid Homeostasis and Cardiovascular Functions
Current Pharmaceutical Design